Aug 23 (Reuters) - British Drugmaker GlaxoSmithKlineon Friday said its experimental cancer treatment belantamabmafodotin met the primary goal of a study for the treatment ofpatients with a type of blood cancer.
Two doses of the drug, also called GSK2857916, boostedresponse rates in adults who received prior treatment formultiple myeloma, a cancer that forms in white blood cells, GSKsaid, adding that it intends to submit data from the trial forregulatory filings.(Reporting by Pushkala Aripaka in Bengaluru; editing by PatrickGraham)